Key clinical point: Patients with acute myeloid leukemia and minimal residual disease before transplant require aggressive interventions to prevent relapse.

Major finding: The presence of an AML variant in blood was associated with worse overall survival and disease-free survival after reduced-intensity conditioning pretransplant, but not after myeloablative conditioning.

Study details: A subcohort of a randomized phase 3 trial comparing conditioning regimens prior to allogeneic stem cell transplant for AML.

Disclosures: The study was supported by the National Institutes of Health. Dr. Hourigan reported research funding from Merck and Sellas Life Sciences AG, research collaboration with Qiagen and Archer, advisory board participation as an NIH official duty for Janssen and Novartis, and part-time employment with the Johns Hopkins School of Medicine.